SEVERE EOSINOPHILIC ASTHMA

This Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…

This study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control severe asthma. Researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearabl…

This study looked at 43 adults in Taiwan with severe eosinophilic asthma who were already prescribed benralizumab. Researchers tracked changes in asthma control using a standard questionnaire over time. The goal was to see how well the drug works in everyday medical practice, not…

This study looked at how well benralizumab (Fasenra) works for people with severe eosinophilic asthma in real-world clinics across the Gulf, Latin America, and India. Researchers tracked 291 patients to see if their asthma control improved over time using a standard questionnaire…

This completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during rou…

This study followed 106 adults with severe eosinophilic asthma in Poland who received mepolizumab injections every 4 weeks for at least a year. Researchers tracked asthma attacks and the need for oral steroids before and during treatment. The goal was to see if the drug helps con…

This study looks at how mepolizumab (Nucala), a treatment for severe eosinophilic asthma, impacts emotions and mental well-being in patients and their partners. Researchers will track changes in feelings like anxiety, depression, and stress using questionnaires and interviews. Th…

This study tested whether a CT scan of the lungs could predict which patients with severe eosinophilic asthma would respond well to the drug benralizumab. 59 adults received benralizumab for 48 weeks and had CT scans at the start, middle, and end of treatment. The goal was to see…

This study looked at how mepolizumab, a biologic drug, changes inflammation in people with severe eosinophilic asthma. Researchers measured immune and metabolic markers in the nose, lungs, and blood of 15 adults. The goal was to better understand the drug's full impact beyond jus…

This completed study looked back at medical records of 74 adults in Portugal with severe eosinophilic asthma who were treated with benralizumab. Researchers wanted to describe patient characteristics, treatment patterns, and outcomes in real-world settings. The study did not test…